The complement system in inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 20, Issue 9, 2014, Pages 1628-1637

  Jain, Umang ^a   Otley, Anthony R ^a,b   Van Limbergen, Johan ^a   Stadnyk, Andrew W ^a  

^a IWK HEALTH CENTRE   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; COMPLEMENT INHIBITOR; ECULIZUMAB; GLYCOPROTEIN;

ADAPTIVE IMMUNITY; ANTIGEN ANTIBODY COMPLEX; COMPLEMENT ACTIVATION; COMPLEMENT DISORDER; COMPLEMENT SYSTEM; GENE MUTATION; GENETIC ASSOCIATION; IMMUNOMODULATION; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; INNATE IMMUNITY; NONHUMAN; OPSONIZATION; PATHOGENESIS; PHAGOCYTOSIS; PRIORITY JOURNAL; REVIEW; ANIMAL; HUMAN; IMMUNOLOGY;

ANIMALS; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; HUMANS; IMMUNITY, INNATE; INFLAMMATORY BOWEL DISEASES;

EID: 84925853399     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000056     Document Type: Review

References (97)

1. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119-124.
2. Van Limbergen J, Redford-Smith G, Satsangi J. Advances in IBD genetics. Nat Rev Gastroenterol Hepatol. 2014;11:372-385.
3. Browning BL, Huebner C, Petermann I, et al. Has toll-like receptor 4 been prematurely dismissed as an inflammatory bowel disease gene? Association study combined with meta-analysis shows strong evidence for association. Am J Gastroenterol. 2007;102:2504-2512.
4. Rioux JD, Silverberg MS, Daly MJ, et al. Genomewide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci. Am J Hum Genet. 2000;66:1863-1870.
5. Mokry M, Middendorp S, Wiegerinck CL, et al. Many inflammatory bowel disease risk loci include regions that regulate gene expression in immune cells and the intestinal epithelium. Gastroenterology. 2014;146: 1040-1047.
6. Zou L, Feng Y, Li Y, et al. Complement factor B is the downstream effector of TLRs and plays an important role in a mouse model of severe sepsis. J Immunol. 2013;191:5625-5635.
7. Hajishengallis G, Lambris JD. Crosstalk pathways between Toll-like receptors and the complement system. Trends Immunol. 2010;31:154-163.
8. Kolev M, Le Friec G, Kemper C. The role of complement in CD4(+) T cell homeostasis and effector functions. Semin Immunol. 2013;25: 12-19.
9. Degn SE, Thiel S. Humoral pattern recognition and the complement system. Scand J Immunol. 2013;78:181-193.
10. Ricklin D, Lambris JD. Complement in immune and inflammatory disorders: therapeutic interventions. J Immunol. 2013;190:3839-3847.
11. Ehrnthaller C, Ignatius A, Gebhard F, et al. New insights of an old defense system: structure, function, and clinical relevance of the complement system. Molr Med. 2011;17:317-329.
12. Huber-Lang M, Sarma JV, Zetoune FS, et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med. 2006;12: 682-687.
13. Scaldaferri F, Lancellotti S, Pizzoferrato M, et al. Haemostatic system in inflammatory bowel diseases: new players in gut inflammation. World J Gastroenterol. 2011;17:594-608.
14. Owczarek D, Cibor D, Glowacki MK, et al. Inflammatory bowel disease: epidemiology, pathology and risk factors for hypercoagulability. World J Gastroenterol. 2014;20:53-63.
15. Dahlbäck B. C4b-binding protein: a forgotten factor in thrombosis and hemostasis. Semin Thromb Hemost. 2011;37:355-361.
16. Deban L, Bottazzi B, Garlanda C, et al. Pentraxins: multifunctional proteins at the interface of innate immunity and inflammation. Biofactors. 2009;35:138-145.
17. Cornillie F, Hanauer SB, Diamond RH, et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut. 2014. doi:10.1136/gutjnl- 2012-304094.
18. Jürgens M, Mahachie John JM, Cleynen I, et al. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2011;9:421-427.
19. Zimmermann-Nielsen E, Agnholt J, Thorlacius-Ussing O, et al. Complement activation in plasma before and after infliximab treatment in Crohn disease. Scand J Gastroenterol. 2003;38:1050-1054.
20. Carroll MC, Isenman DE. Regulation of humoral immunity by complement. Immunity. 2012;37:199-207.
21. Strainic MG, Liu J, Huang D, et al. Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. Immunity. 2008;28:425-435.
22. Kemper C, Chan AC, Green JM, et al. Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature. 2003;421:388-392.
23. Heeger PS, Kemper C. Novel roles of complement in T effector cell regulation. Immunobiology. 2012;217:216-224.
24. Cardone J, Al-Shouli S, Kemper C. A novel role for CD46 in wound repair. Front Immunol. 2011;2:28.
25. Poon IKH, Hulett MD, Parish CR. Molecular mechanisms of late apoptotic/necrotic cell clearance. Cell Death Differ. 2010;17:381-397.
26. McKeage K. Eculizumab: a review of its use in paroxysmal nocturnal haemoglobinuria. Drugs. 2011;71:2327-2345.
27. Rathbone J, Kaltenthaler E, Richards A, et al. A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS). BMJ Open. 2013;3:e003573
28. Sahu A, Kay BK, Lambris JD. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library. J Immunol. 1996;157:884-891.
29. Qu H, Ricklin D, Bai H, et al. New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties. Immunobiology. 2013;218:496-505.
30. Zuraw BL, Kalfus I. Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema. Am J Med. 2012;125:938.e1-e7.
31. Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol. 2008;26:513-533.
32. Rogosnitzky M, Danks R, Holt D. Intravenous immunoglobulin for the treatment of Crohn's disease. Autoimmun Rev. 2012;12:275-280.
33. Lutz HU, Späth PJ. Anti-inflammatory effect of intravenous immunoglobulin mediated through modulation of complement activation. Clin Rev Allergy Immunol. 2005;29:207.
34. Andoh A, Fujiyama Y, Sumiyoshi K, et al. Local secretion of complement C3 in the exocrine pancreas: ductal epithelial cells as a possible biosynthetic site. Gastroenterology. 1996;110:1919-1925.
35. Laufer J, Oren R, Goldberg I, et al. Cellular localization of complement C3 and C4 transcripts in intestinal specimens from patients with Crohn's disease. Clin Exp Immunol. 2000;120:30-37.
36. Sugihara T, Kobori A, Imaeda H, et al. The increased mucosal mRNA expressions of complement C3 and interleukin-17 in inflammatory bowel disease. Clin Exp Immunol. 2010;160:386-393.
37. Riordan SM, McIver CJ, Wakefield D, et al. Local and systemic complement activity in small intestinal bacterial overgrowth. Dig Dis Sci. 1997; 42:1128-1136.
38. Ahrenstedt O, Knutson L, Nilsson B, et al. Enhanced local production of complement components in the small intestines of patients with Crohn's disease. N Engl J Med. 1990;322:1345-1349.
39. Riordan SM, McIver CJ, Thomas MC, et al. The expression of complement protein 4 and IgG3 in luminal secretions. Scand J Gastroenterol. 1996;31:1098-1102.
40. Elmgreen J, Both H, Binder V. Familial occurrence of complement dysfunction in Crohn's disease: correlation with intestinal symptoms and hypercatabolism of complement. Gut. 1985;26:151-157.
41. Andoh A, Fujiyama Y, Bamba T, et al. Differential cytokine regulation of complement C3, C4, and factor B synthesis in human intestinal epithelial cell line, Caco-2. J Immunol. 1993;151:4239-4247.
42. Bernet-Camard MF, Coconnier MH, Hudault S, et al. Differential expression of complement proteins and regulatory decay accelerating factor in relation to differentiation of cultured human colon adenocarcinoma cell lines. Gut. 1996;38:248-253.
43. Cortes C, Ohtola JA, Saggu G, et al. Local release of properdin in the cellular microenvironment: role in pattern recognition and amplification of the alternative pathway of complement. Front Immunol. 2013;3:412.
44. Wirthmueller U, Dewald B, Thelen M, et al. Properdin, a positive regulator of complement activation, is released from secondary granules of stimulated peripheral blood neutrophils. J Immunol. 1997;158:4444-4451.
45. Berstad AE, Brandtzaeg P. Expression of cell membrane complement regulatory glycoproteins along the normal and diseased human gastrointestinal tract. Gut. 1998;42:522-529.
46. Medof ME, Walter EI, Rutgers JL, et al. Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids. J Exp Med. 1987;165:848-864.
47. Andoh A, Kinoshita K, Rosenberg I, et al. Intestinal trefoil factor induces decay-accelerating factor expression and enhances the protective activities against complement activation in intestinal epithelial cells. J Immunol. 2001;167:3887-3893.
48. Cao Q, McIsaac SM, Stadnyk AW. Human colonic epithelial cells detect and respond to C5a via apically expressed C5aR through the ERK pathway. Am J Physiol Cell Physiol. 2012;302:C1731-C1740.
49. Halstensen TS, Mollnes TE, Garred P, et al. Surface epithelium related activation of complement differs in Crohn's disease and ulcerative colitis. Gut. 1992;33:902-908.
50. Halstensen TS, Mollnes TE, Garred P, et al. Epithelial deposition of immunoglobulin G1 and activated complement (C3b and terminal complement complex) in ulcerative colitis. Gastroenterology. 1990;98:1264-1271.
51. Ueki T, Mizuno M, Uesu T, et al. Distribution of activated complement, C3b, and its degraded fragments, iC3b/C3dg, in the colonic mucosa of ulcerative colitis (UC). Clin Exp Immunol. 1996;104:286-292.
52. Lin F, Spencer D, Hatala DA, et al. Decay-accelerating factor deficiency increases susceptibility to dextran sulfate sodium-induced colitis: role for complement in inflammatory bowel disease. J Immunol. 2004;172:3836-3841.
53. Hodgson HJF, Potter BJ, Jewell DP. C3 metabolism in ulcerative colitis and Crohn's disease. Clin Exp Immunol. 1977;28:490-495.
54. Teisberg P, Gjone E. Humoral immune system activity in inflammatory bowel disease. Scand J Gastroenterol. 1975;10:545-549.
55. Elmgreen J, Berkowicz A, Sorensen H. Hypercatabolism of complement in Crohn's disease-assessment of circulating C3c. Acta Med Scand. 1983;214:403-407.
56. Hodgson HJF, Potter BJ, Jewell DP. Humoral immune system in inflammatory bowel disease: I. Complement levels. Gut. 1977;18:749-753.
57. Feinstein PA, Kaplan SR, Thayer WR. The alternate complement pathway in inflammatory bowel disease. Quantitation of the C3 proactivator (factor B) protein. Gastroenterology. 1976;70:181-185.
58. Ward M, Eastwood MA. Serum C3 and C4 complement components in ulcerative colitis and Crohn's disease. Digestion. 1975;13:100-103.
59. Richens ER, Thorpe CM, Bland P, et al. Circulating immune complexes in Crohn's disease. Their characterization and interrelationship with components of the complement system. Dig Dis Sci. 1982;27:129-138.
60. Bene L, Füst G, Fekete B, et al. High normal serum levels of C3 and C1 inhibitor, two acute phase proteins belonging to the complement system, occur more frequently in patients with Crohn's disease than ulcerative colitis. Dig Dis Sci. 2003;48:1186-1192.
61. Lake AM, Stitzel AE, Urmson JR, et al. Complement alterations in inflammatory bowel disease. Gastroenterology. 1979;76:1374-1379.
62. Elmgreen J, Berkowicz A, Sorensen H. Defective release of C5a related chemo-attractant activity from complement in Crohn's disease. Gut. 1983; 24:525-531.
63. Zimmermann-Nielsen E, Grønbaek H, Dahlerup JF, et al. Complement activation capacity in plasma before and during high-dose prednisolone treatment and tapering in exacerbations of Crohn's disease and ulcerative colitis. BMC Gastroenterol. 2005;5:31.
64. Sandahl TD, Kelsen J, Dige A, et al. The lectin pathway of the complement system is downregulated in Crohn's disease patients who respond to anti-TNF-α therapy. J Crohns Colitis. 2014;8:521-528.
65. Matsubaysahi T, Kaneko S, Shimizu M, et al. Colitis associated with deficiency of the sixth component of complement and congenital chronic neutropenia. Acta Paediatr. 2001;90:1211-1212.
66. Marks DJB, Seymour CR, Sewell GW, et al. Inflammatory bowel disease in patients with adaptive and complement immunodeficiency disorders. Inflamm Bowel Dis. 2010;16:1984-1992.
67. Heitzeneder S, Seidel M, Förster-Waldl E, et al. Mannan-binding lectin deficiency-Good news, bad news, doesn't matter? Clin Immunol. 2012; 143:22-38.
68. Matsushita M. Ficolins in complement activation. Mol Immunol. 2013;55: 22-26.
69. Schaffer T, Flogerzi B, Schoepfer AM, et al. Increased titers of anti-Saccharomyces cerevisiae antibodies in Crohn's disease patients with reduced H-ficolin levels but normal MASP-2 activity. J Crohns Colitis. 2013;7:e1-e10.
70. Worthley DL, Bardy PG, Gordon DL, et al. Mannose-binding lectin and maladies of the bowel and liver. World J Gastroenterol. 2006;12: 6420-6428.
71. Müller S, Schaffer T, Flogerzi B, et al. Mannan-binding lectin deficiency results in unusual antibody production and excessive experimental colitis in response to mannose-expressing mild gut pathogens. Gut. 2010;59: 1493-1500.
72. Papp M, Lakatos PL, Harsfalvi J, et al. Mannose-binding lectin level and deficiency is not associated with inflammatory bowel diseases, disease phenotype, serology profile, and NOD2/CARD15 genotype in a large Hungarian cohort. Hum Immunol. 2010;71:407-413.
73. Rector A, Lemey P, Laffut W, et al. Mannan-binding lectin (MBL) gene polymorphisms in ulcerative colitis and Crohn's disease. Genes Immun. 2001;2:323-328.
74. Sivaram G, Tiwari SK, Bardia A, et al. Association of genetic variants of mannan-binding (MBL) lectin-2 gene, MBL levels and function in ulcerative colitis and Crohn's disease. Innate Immun. 2010;17:526-531.
75. Wang FY, Arisawa T, Tahara T, et al. The role of mannan-binding lectin (MBL) gene polymorphism in ulcerative colitis. J Clin Biochem Nutr. 2008;42:54-58.
76. Bak-Romaniszyn L, Szala A, Sokolowska A, et al. Mannan-binding lectin deficiency in pediatric patients with inflammatory bowel disease. Scand J Gastroenterol. 2011;46:1275-1278.
77. Kovacs M, Papp M, Lakatos PL, et al. Low mannose-binding lectin (MBL) is associated with paediatric inflammatory bowel diseases and ileal involvement in patients with Crohn disease. J Crohns Colitis. 2013;7: 134-141.
78. Kitano A, Matsumoto T, Nakamura S, et al. Multifunctional effects of anticomplementary agent K-76 on carrageenan-induced colitis in rabbits. Clin Exp Immunol. 1993;94:348-353.
79. Kitano A, Matsumoto T, Nakamura S, et al. New treatment of ulcerative colitis with K-76. Dis Colon Rectum. 1992;35:560-567.
80. McCole DF, Otti B, Newsholme P, et al. Complement activation of electrogenic ion transport in isolated rat colon. Biochem Pharmacol. 1997;54: 1133-1137.
81. Woodruff TM, Arumugam TV, Sheils IA, et al. A potent human C5a receptor antagonist protects against disease pathology in a rat model of inflammatory bowel disease. J Immunol. 2003;171:5514-5520.
82. Jain U, Woodruff TM, Stadnyk AW. The C5a receptor antagonist PMX205 ameliorates experimentally induced colitis associated with increased IL-4 and IL-10. Br J Pharmacol. 2013;168:488-501.
83. Chen G, Yang Y, Gao X, et al. Blockade of complement activation product C5a activity using specific antibody attenuates intestinal damage in trinitrobenezene sulfonic acid induced model of colitis. Lab Invest. 2010;91:472-483.
84. Johswich K, Martin M, Bleich A, et al. Role of the C5a receptor (C5aR) in acute and chronic dextran sulfate-induced models of inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:1812-1823.
85. Naito Y, Takagi T, Handa O, et al. Enhanced intestinal inflammation induced by dextran sulfate sodium in tumor necrosis factor-alpha deficient mice. J Gastroenterol Hepatol. 2003;18:560-569.
86. Höpken UE, Lu B, Gerard NP, et al. The C5a chemoattractant receptor mediates mucosal defence to infection. Nature. 1996;383:86-89.
87. Deguchi Y, Andoh A, Inatomi O, et al. Development of dextran sufate sodium-induced colitis is aggravated in mice genetically deficient for complement C5. Int J Mol Med. 2005;16:605-608.
88. Aomatsu T, Imaeda H, Takahashi K, et al. Neutralization of complement component C5 ameliorates the development of dextran sulfate sodium (DSS)-colitis in mice. J Clin Biochem Nutr. 2013;52:72-75.
89. Mollness TE, Nilsson PH. Letter to Editor. J Clin Biochem Nutr. 2013;53: 253-254.
90. Berndt BE, Zhang M, Chen GH, et al. The role of dendritic cells in the development of acute dextran sulfate sodium colitis. J Immunol. 2007; 179:6255-6262.
91. Qualls JE, Kaplan AM, Van Rooijen N, et al. Suppression of experimental colitis by intestinal mononuclear phagocytes. J Leukoc Biol. 2006;80: 802-815.
92. Vieira AT, Fagundes CT, Alessandri AL, et al. Treatment with a novel chemokine-binding protein or eosinophil lineage-ablation protects mice from experimental colitis. Am J Pathol. 2009;175: 2382-2391.
93. Lalli PN, Strainic MG, Yang M, et al. Locally produced C5a binds to T cell-expressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosis. Blood. 2008;112:1759-1766.
94. Langer HF, Chung KJ, Orlova VV, et al. Complement-mediated inhibition of neovascularization reveals a point of convergence between innate immunity and angiogenesis. Blood. 2010;116:4395-4403.
95. Li R, Coulthard LG, Wu M, et al. C5L2: a controversial receptor of complement anaphylatoxin, C5a. FASEB J. 2013;27:855-864.
96. Schepp-Berglind J, Atkinson C, Elvington M, et al. Complement-dependent injury and protection in a murine model of acute dextran sulfate sodiuminduced colitis. J Immunol. 2012;188:6309-6318.
97. Ogden CA, deCathelineau A, Hoffmann PR, et al. C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells. J Exp Med. 2001;194: 781-795.